Re: "Why buy the cow"
YES 30% Equity Stake at $40 a share.
SM and Adrian Woolfson and his top Management know that SGMO will be worth MUCH MUCH More than even $5B within FIVE Years.
Read Woolfson's BIO and his experience and insider information as a PFE Executive.
Read the BIOs of SM Leadership Team on the $GMO web site..and you will see everything has changed . Fortunately for me these guys know what SGMO is worth NOW and Going Forward..
They don'y use RYNO's Rear View Mirror
Adrian Woolfson, BM, BCh, PhD, has served as Sangamo’s Executive Vice President of Research & Development since January 2019. Dr. Woolfson has over a decade of biopharmaceutical industry experience in drug discovery, medical affairs and early and late stage clinical development. Most recently, he served as Chief Medical Officer at Nouscom AG, a genetic cancer vaccine biotechnology company based in Basel, Switzerland, where he led the development of the company’s off-the-shelf and personalized neoantigen vaccine and oncolytic virus strategy. Prior to Nouscom, Dr. Woolfson served as Global Clinical Leader, Early and Late Stage Immuno-Oncology/Hematology at Pfizer Inc. in New York, and was responsible for defining Pfizer’s hematology immuno-oncology strategy and building its immuno-oncology hematological malignancies portfolio. Prior to that he was the Global Lead for Pfizer’s SMO inhibitor glasdegib, which received FDA approval in 2018. From 2007 to 2013, Dr. Woolfson held roles of increasing responsibility at Bristol-Myers Squibb, including Global Medical Lead for a first-in-human CDC7 inhibitor and selective JAK2 inhibitor.